4D Molecular Therapeutics, Inc. - FDMT STOCK NEWS

4D Molecular Therapeutics (FDMT) reported significant advancements in Q2 2021, achieving total revenue of $14.6 million, up from $3.6 million in Q2 2020, largely due to collaboration adjustments with Roche. The company continues to expand its cGMP manufacturing facilities and has made key leadership appointments. Net loss decreased to $7.6 million compared to $15.2 million in the previous year. Upcoming milestones include clinical data announcements for multiple product candidates in the ophthalmology sector.

4D Molecular Therapeutics (Nasdaq: FDMT) announced initial safety data from its Phase 1 clinical trials for 4D-110, targeting choroideremia, and 4D-125, for X-linked retinitis pigmentosa. Both candidates demonstrated good tolerability with no dose-limiting toxicities across 12 patients. Additionally, the company regained full rights to 4D-110 following Roche's termination of their collaboration agreement. Moving forward, 4DMT plans to analyze clinical data and submit a new study protocol to the FDA, aiming for further development of 4D-110 and upcoming milestones in their pipeline.

4D Molecular Therapeutics (Nasdaq: FDMT) has appointed Carolyne Zimmermann as the new Chief Business Officer. Zimmermann brings nearly 20 years of experience in life sciences from her roles at Johnson & Johnson Innovation and Novartis Pharmaceuticals. The appointment is aimed at leveraging her expertise in corporate development to enhance the company's gene therapy platform, Therapeutic Vector Evolution. 4DMT focuses on developing targeted gene therapies in ophthalmology, cardiology, and pulmonology, currently running three clinical trials for various genetic conditions.

4D Molecular Therapeutics (Nasdaq: FDMT) has announced participation in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 2:30 p.m. PT. This event will feature a fireside chat available via a live audio webcast on the company's website, with a replay accessible for two weeks after the event. 4DMT focuses on advancing gene therapy through its Therapeutic Vector Evolution platform, targeting areas like ophthalmology and cardiology, with ongoing clinical trials for multiple diseases including XLRP, choroideremia, and Fabry disease.

4D Molecular Therapeutics (FDMT) reported its Q1 2021 financial results, marking a notable progress as a public company. Cash and cash equivalents stood at $259.9 million, sufficient to fund operations into mid-2023. However, total revenue decreased to $2.0 million from $3.5 million year-over-year, largely due to reduced revenue from collaborations. R&D expenses decreased slightly to $12.8 million, while G&A expenses rose to $5.5 million. The net loss increased to $16.4 million from $13.2 million in the previous year.

4D Molecular Therapeutics (Nasdaq: FDMT) has announced promising preclinical data for its dual transgene gene therapy, 4D-150, aimed at treating wet AMD and DME. Presenting at the ASGCT Annual Meeting, the therapy demonstrated complete suppression of CNV lesions in non-human primates at the lowest tested dose of 1E11 vg/eye. The acute biodistribution study showed significant ocular aflibercept expression with no adverse ocular effects. This novel approach targets multiple VEGF family members, potentially enhancing efficacy in patients resistant to existing treatments.

4D Molecular Therapeutics (Nasdaq: FDMT) announced a collaboration with UC Berkeley to enhance its Therapeutic Vector Evolution platform using machine learning. This partnership aims to expand the company’s vector patent portfolio and improve bioinformatics capabilities. 4DMT boasts the largest biodistribution datasets and has conducted over 15 vector selection programs. The company is developing several product candidates in clinical trials, focusing on ophthalmology, cardiology, and pulmonology, with safety and efficacy yet to be determined by regulatory authorities.

4D Molecular Therapeutics (Nasdaq: FDMT) announced its participation in the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 2:00 p.m. PT. The presentation will be accessible via a live audio webcast on the company’s website, with a replay available for two weeks post-event.

The company focuses on targeted gene therapy using its Therapeutic Vector Evolution platform. Currently, 4DMT is conducting three clinical trials: 4D-125 for XLRP, 4D-110 for choroideremia, and 4D-310 for Fabry disease.

4D Molecular Therapeutics (Nasdaq: FDMT) announced that abstracts for three of its gene therapy product candidates have been accepted for oral presentations at two significant medical conferences. The presentations will focus on:

• 4D-150 for wet AMD and DME, highlighting its anti-angiogenic mechanisms and preclinical efficacy.
• 4D-310 for Fabry disease.
• 4D-710 for cystic fibrosis lung disease.

The presentations are scheduled for the ASGCT Annual Meeting from May 11-14 and the ATS International Conference from May 14-19, 2021.